Exchange: NASDAQ·Updated 07:59 PM EDT
AZN logo

AZNAstraZeneca PLC

$169.26
$0.99
(0.59%)
Today
Closed $169.26
$1.25
(0.74%)
After Hours
Reported EarningsApr 29
Mkt Cap$262.5B
Vol2.01M
News
all
press releases
EU Clears AZN's Etcamah Combo for First-Line ER-Positive Breast Cancer
AstraZeneca secures EU approval for Etcamah in combination with a CDK4/6 inhibitor for first-line treatment of advanced ER-positive breast cancer patients.
Zacks
More News
J&J's Innovative Medicine Unit Proves Its Resilience in Q2
JNJ's Innovative Medicine unit posts strong Q2 growth despite Stelara's patent loss. See what's fueling momentum into H2 2026.
Zacks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN PR Newswire NEW YORK, July 23, 2026 NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is...
PR Newswire
Will GSK's Specialty Medicines Boost Q2 Revenue Growth?
GSK's Specialty Medicines unit is expected to post double-digit CER growth in Q2, driven by newer HIV, RI&I and oncology drugs despite legacy pressures.
Zacks
AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AstraZeneca PLC (AstraZeneca or the Company) (NASDAQ: AZN) for violations of the securities laws.The investigation focuses on whether the Company issued false...
Business Wire
Will AbbVie's Oncology Franchise Remain Under Pressure in Q2?
ABBV's Q2 oncology revenues may edge lower as Imbruvica weakness outweighs gains from Venclexta and newer cancer therapies.
Zacks
Stay Ahead of the Game With Astrazeneca (AZN) Q2 Earnings: Wall Street's Insights on Key Metrics
Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zacks
Will Keytruda Remain the Driving Force Behind Merck's Q2 Performance?
Keytruda is expected to drive another strong quarter for MRK, with investors watching Q2 sales and management's outlook ahead of the drug's 2028 patent expiry.
Zacks
Why CELC Stock Declined 15% in a Week Despite a Major FDA Win
Celcuity slides 15% despite FDA approval of Revtorpyk as investors focus on a late Q3 2026 launch that delays commercial sales and near-term revenues.
Zacks
Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know
Astrazeneca (AZN) closed the most recent trading day at $164.52, moving 2.59% from the previous trading session.
Zacks
<
1
2
...
>

Advertisement|Remove ads.